drugset / Trial / NCT05147337
A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants
RandomizedParallel-groupDouble-blindOther
Summary
The primary objective of this study is to evaluate the safety, tolerability, and plasma pharmacokinetic (PK) of E2511 following multiple oral doses in healthy adult participants.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-08-18
- Completion
- 2022-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E2511 | Unknown | 10 mg | Oral |
| Subject | E2511 | Unknown | 20 mg | Oral |
| Subject | E2511 | Unknown | 40 mg | Oral |
| Subject | E2511 | Unknown | 80 mg | Oral |
Indications
No indication recorded.